Curanex Pharmaceuticals Inc CURX
Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026
Curanex Pharmaceuticals Inc (CURX) is a healthcare company listed in the US with a market value of about $8M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -43%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Curanex Pharmaceuticals
Curanex Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 0 of the last 2 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Revenue | — | — |
| Net income | -$4M | -$361506 |
| Free cash flow | — | — |
| EPS (diluted) | $-0.17 | $-0.03 |
| Net margin | — | — |
| ROIC | -28.9% | -57.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Curanex Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Curanex Pharmaceuticals pay a dividend?
Not currently.
Is Curanex Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Curanex Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.